Neuralstem Inc. (CUR)

0.46
NASDAQ : Health Technology
Prev Close 0.46
Day Low/High 0.45 / 0.47
52 Wk Low/High 0.25 / 1.78
Avg Volume 225.30K
Exchange NASDAQ
Shares Outstanding 20.01M
Market Cap 9.11M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Neuralstem Appoints David J. Mazzo, Ph.D., To Board Of Directors

Neuralstem Appoints David J. Mazzo, Ph.D., To Board Of Directors

GERMANTOWN, Md., May 6, 2019 /PRNewswire/ -- Neuralstem, Inc.

Neuralstem To Expand Pipeline As Part Of Aggressive Growth Effort

Neuralstem To Expand Pipeline As Part Of Aggressive Growth Effort

Neuralstem Engages Strategic Advisors to Evaluate Dozens of New Technologies

First Week Of CUR February 2019 Options Trading

First Week Of CUR February 2019 Options Trading

Investors in Neuralstem Inc saw new options begin trading this week, for the February 2019 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 189 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Intra-Cellular Leaps; Schizophrenia Drug Shows Less Side Effects-Biotech Movers

Intra-Cellular Leaps; Schizophrenia Drug Shows Less Side Effects-Biotech Movers

Standard treatments can cause motor side effects and/or weight gain, cardiovascular complications, dyslipidemia, and hyperglycemia.

Neuralstem Reports Last Subject Out In Phase 2 Trial Of NSI-189 For Major Depressive Disorder

Top Line Results Expected in 3Q 2017

Neuralstem Reports First Quarter 2017 Fiscal Results Provides Clinical And Business Update

Phase 2 MDD clinical trial results expected in 3Q17, Extended runway of cash into 3Q18

Neuralstem Expands Phase 1 Safety Trial Of NSI-566 Neural Stem Cells In Spinal Injury

Investigating New Patient Cohort with Cervical Injury

TheStreet Quant Rating: D- (Sell)